Notes to Consolidated
Financial Statements
Unaudited
Note
1. Basis of Presentation
The
accompanying unaudited interim consolidated financial statements have been prepared in accordance with accounting principles generally
accepted in the United States of America (“GAAP”) for interim financial information and pursuant to the instructions
to Form 10-Q and Article 8 of Regulation S-X of the United States Securities and Exchange Commission (“SEC”).
Certain information or footnote disclosures normally included in financial statements prepared in accordance with accounting principles
generally accepted in the United States of America have been condensed or omitted, pursuant to the rules and regulations of the SEC
for interim financial reporting. Accordingly, they do not include all the information and footnotes necessary for a comprehensive
presentation of financial position, results of operations, or cash flows. It is our opinion, however, that the accompanying unaudited
interim consolidated financial statements include all adjustments, consisting of a normal recurring nature, which are necessary
for a fair presentation of the financial position, operating results and cash flows for the periods presented.
The
accompanying unaudited interim consolidated financial statements should be read in conjunction with our Annual Report on Form 10-K
for the year ended November 30, 2015 as filed with the SEC, which contains the audited financial statements and notes thereto,
together with Management’s Discussion and Analysis, for the years ended November 30, 2015 and 2014. The financial information
as of February 29, 2016 is derived from the audited financial statements presented in our Annual Report on Form 10-K for the year
ended November 30, 2015. The interim results for the three months ended February 29, 2016 are not necessarily indicative of the
results to be expected for the year ending November 30, 2016 or for any future interim periods.
Derivative
Liabilities
Fair
Value of Financial Instruments
The
Company’s financial instruments consist of cash and cash equivalents, accounts payable and accrued expenses and shareholder
loans. The carrying amount of these financial instruments approximates fair value due either to length of maturity or interest
rates that approximate prevailing market rates unless otherwise disclosed in these financial statements.
Financial
assets and liabilities recorded at fair value in our balance sheets are categorized based upon a fair value hierarchy established
by GAAP, which prioritizes the inputs used to measure fair value into the following levels:
Fair
Value of Financial Instruments
Level
1— Quoted market prices in active markets for identical assets or liabilities at the measurement date.
Level
2— Quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets and
liabilities in markets that are not active; or other inputs that are observable and can be corroborated by observable market data.
Level
3— Inputs reflecting management’s best estimates and assumptions of what market participants would use in pricing
assets or liabilities at the measurement date. The inputs are unobservable in the market and significant to the valuation of the
instruments.
A
financial instrument’s categorization within the valuation hierarchy is based upon the lowest level of input that is significant
to the fair value measurement.
Financial
assets and liabilities measured at fair value on a recurring basis are summarized below for the quarter ended February 29, 2016
|
|
Level 1
|
|
|
Level 2
|
|
|
Level 3
|
|
|
Total
|
|
Assets
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Securities -available for sale
|
|
$
|
-
|
|
|
$
|
-
|
|
|
$
|
-
|
|
|
$
|
-
|
|
Liabilities
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Derivative Financial Instruments
|
|
$
|
-
|
|
|
$
|
-
|
|
|
$
|
26,116
|
|
|
$
|
26,116
|
|
The
following table presents details of the Company’s level 3 derivative liabilities as of February 29, 2016 and November 30,
2015:
|
|
Amount
|
|
Balance November 30, 2015
|
|
$
|
60,356
|
|
|
|
|
|
|
Change in fair market value of derivative liabilities
|
|
|
(34,240
|
)
|
Balance February 29, 2016
|
|
$
|
26,116
|
|
BioPower Operations
Corporation and Subsidiaries
Notes to Consolidated
Financial Statements
February 29, 2016
Unaudited
Note
2. Going Concern
As
reflected in the accompanying consolidated financial statements, the Company had a net loss of $1,019,409 and $254,393, for the
three months ended February 29, 2016 and February 28, 2015, respectively, and net cash used in operations of $31,066 and $58,805
for the three months ended February 29, 2016 and February 28, 2015, respectively. Additionally, the Company had a working capital
deficit of $4,401,419, for the three months ended February 29, 2016 and a stockholders’ deficit of $4,385,263 at February
29, 2016. These factors raise substantial doubt about the Company’s ability to continue as a going concern.
The
ability of the Company to continue as a going concern is dependent on Management’s plans, which include potential asset
acquisitions, mergers or business combinations with other entities, further implementation of its business plan and continuing
to raise funds through debt and/or equity financings. The Company will likely rely upon related party debt and/or equity financing
in order to ensure the continuing existence of the business.
The
accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization
of assets and the satisfaction of liabilities in the normal course of business. These financial statements do not include any
adjustments relating to the recovery of the recorded assets or the classification of the liabilities that might be necessary should
the Company be unable to continue as a going concern.
Note
3. Equipment
At
February 29, 2016 and February 28, 2015, equipment consists of the following:
|
|
2016
|
|
|
2015
|
|
|
Estimated Useful Life
|
Computer Equipment
|
|
$
|
36,800
|
|
|
$
|
27,760
|
|
|
5 years
|
Testing Equipment
|
|
|
-
|
|
|
|
20,366
|
|
|
3 years
|
Less: Accumulated depreciation
|
|
|
(27,581
|
)
|
|
|
(29,977
|
)
|
|
|
Equipment, net
|
|
$
|
9,219
|
|
|
$
|
18,149
|
|
|
|
Depreciation
expense was $1,657 and $3,085 for the three months ended February 29, 2016 and February 28, 2015, respectively.
Note
4. Notes Payable and Convertible Debt
Notes
payable consists of the following:
|
|
Balance
|
|
|
Interest Rate
|
|
|
Maturity
|
|
Balance
– November 30, 2015
|
|
$
|
132,500
|
|
|
|
8
|
%
|
|
|
Various
|
|
Borrowings
|
|
|
5,000
|
|
|
|
8
|
%
|
|
|
June
30, 2016
|
|
Balance
– February 29, 2016
|
|
$
|
137,500
|
|
|
|
|
|
|
|
|
|
In
January, 2016 a third party investor advanced $5,000, at 8% interest, which is due on June 30, 2016.
Convertible
debt consists of the following:
|
|
Balance
|
|
|
Interest Rate
|
|
|
Maturity
|
|
|
Conversion Price
|
|
Balance – November 30, 2015
|
|
$
|
189,366
|
|
|
|
8
|
%
|
|
|
Various
|
|
|
|
In
Default
|
|
Reclass non related to related
|
|
|
(74,778
|
)
|
|
|
8
|
%
|
|
|
December 30, 2015
|
|
|
|
0.15
|
|
Debt Discount
|
|
|
49,120
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance – February 29, 2016
|
|
$
|
164,038
|
|
|
|
|
|
|
|
|
|
|
|
|
|
BioPower Operations
Corporation and Subsidiaries
Notes to Consolidated
Financial Statements
February 29, 2016
Unaudited
Accrued
interest on notes payable and convertible debt at February 29, 2016 and November 30, 2015 amounted to $27,343 and $23,316, respectively,
which is included as a component of accounts payable and accrued expenses.
Interest
expense on notes payable and convertible debt with third parties amounted to $49,199 and $3,926 for the three months ended February
29, 2016 and February 28, 2015, respectively.
Note
5. Related Party Transactions
Notes
payable to related parties at February 29, 2016 and November 30, 2015 is $525 and $525, respectively. Convertible notes payable
to related parties at February 29, 2016 and November 30, 2015 is $50,000 and $44,394, respectively.
On
December 15, 2015 a related party investor advanced $25,000 due on or before June 15, 2016. Pursuant to the agreement, the investor
is allowed to convert 100% of the debt at a share price of $0.15. The company accounted for the conversion of loan in accordance
with ASC 470, “Debt with Conversion and Other Options”. The loan was deemed to have a beneficial conversion feature
because the fair value of the stock exceeded the effective conversion price embedded in the loan on the commitment date. Accordingly,
the Company recorded the value of the beneficial conversion feature, which was determined to be $8,333 as a discount to the loan
and a corresponding increase to additional paid in capital.
On
February 18, 2016 a related party investor advanced $16,500 due on or before June 17, 2016. Pursuant to the agreement, the investor
is allowed to convert 100% of the debt at a share price of $0.15. The company accounted for the conversion of loan in accordance
with ASC 470, “Debt with Conversion and Other Options”. The fair market value of the shares on February 18, 2016 was
$0.10 per share and accordingly deemed to have no Beneficial Conversion Factor.
Accrued
interest on related party notes payable and convertible debt at February 29, 2016 and November 30, 2015, amounted to $9,464 and
$4,250, respectively and is a component of accounts payable and accrued expenses – related parties.
Interest
expense on notes payable and convertible debt with related parties amounted to $17,775 and $2,082 for the three months ended February
29, 2016 and February 28, 2015, respectively.
The
Company has separated accounts payable and accrued expenses on the balance sheet to reflect amounts due to related parties primarily
consisting of officer compensation, health insurance, interest on notes and reimbursable expenses to officers for travel, meals
and entertainment, vehicle and other related business expenses.
Note
6. Derivative Liabilities
On
July 23, 2015, the Company entered into a convertible loan agreement with an investor. The Company received a total of $50,000
which bears interest at 8% per annum and is due on December 30, 2016. Interest shall accrue from the advancement date and shall
be payable on December 30, 2016. Any portion of the loan and unpaid interest are convertible at any time at the option of the
lender into shares of common stock of the Company at a conversion price of $0.15 per share. If an equity transaction occurs at
a price below $0.15, then the conversion price will adjust to such price.
On
this date of issuance, the Company recorded a debt discount in the amount of $50,000 in connection with the initial valuation
of the derivative liability of the note to be amortized utilizing the effective interest method of accretion over the term of
the note. Further, the Company recognized a derivative liability of $111,074 and initial loss on derivative liability of $61,074
based on the Black Scholes pricing model. As of February 29, 2016, $21,007 of the debt discount has been amortized. The fair value
of the derivative liability at February 29, 2016 is $26,116 resulting in a gain on the change in fair value of the derivative
of $34,240. The Note is shown net of a derivative debt discount of $28,993 at February 29, 2016. (See Note 4 –Convertible
Debt).
BioPower
Operations Corporation and Subsidiaries
Notes
to Consolidated Financial Statements
February
29, 2016
Unaudited
Since
equity classification is not available for the conversion feature, we were required to bifurcate the embedded conversion feature
and carry it as a derivative liability, at fair value. Derivative financial instrument is carried initially and subsequently at
its fair values.
We
estimated the fair value of the derivative on the inception date, and subsequently, using the Black-Scholes valuation technique,
adjusted for the effect of dilution, because that technique embodies all of the assumptions (including, volatility, expected terms,
and risk free rates) that are necessary to fair value complex derivate instruments.
As
a result of the application of ASC No. 815 in period ended February 29, 2016 the fair value of the conversion feature is summarized
as follows:
|
|
Amount
|
|
Balance November 30, 2015
|
|
$
|
60,356
|
|
Change in fair market value of derivative liabilities
|
|
|
(34,240
|
)
|
Balance February 29, 2016
|
|
$
|
26,116
|
|
The
fair value at the commitment and re-measurement dates for the Company’s derivative liabilities were based upon the following
management assumptions as of February 29, 2016 and commitment date:
BioPower
Operations Corporation and Subsidiaries
Notes
to Consolidated Financial Statements
February
29, 2016
Unaudited
|
|
Commitment Date
|
|
|
February 29, 2016
|
|
|
|
|
|
|
|
|
Expected dividends
|
|
|
-
|
|
|
|
-
|
|
Expected volatility
|
|
|
296.84
|
%
|
|
|
293.61
|
%
|
Expect term
|
|
|
1.44
|
|
|
|
.84
|
|
Risk free interest rate
|
|
|
0.33
|
%
|
|
|
0.62
|
%
|
Note
7. Stockholders’ Deficit
For
the three months ended February 29, 2016:
On
February 24, 2016, the Board of Directors approved the following stock compensation because of the Company not making any cash
payments toward salary during the year ended November 30, 2015. The stock compensation is to be paid by November 30, 2016 provided
the Company has revenues from operations that can provide for the taxes due for the stock compensation, or the stock will be returned
to the Company. The stock will be issued and held by the Transfer Agent until November 30, 2016 and then returned to the Company
or distributed to the employee. The employee has the option to pay the Company for the employer taxes due and their own taxes
due for the stock compensation on or before November 30, 2016.
The company fair valued these shares as of
the date of issuance and recorded $500,000 stock-based compensation for the three months ended February 29, 2016.
Dr.
Neil Williams, CEO G3P
|
|
2,000,000
|
|
common
stock shares
|
Robert
Kohn, CEO BioPower
|
|
1,250,000
|
|
common
stock shares
|
Bonnie
Nelson, Director of Strategy
|
|
1,250,000
|
|
common
stock shares
|
Benjamin
Williams, Sr. Vice President
|
|
500,000
|
|
common
stock shares
|
Total
|
|
5,000,000
|
|
common
stock shares
|
There
are 47,107,680 and 42,107,680 shares outstanding at February 29, 2016 and November 30, 2015, respectively.
Note
8. Commitments and Contingencies
Commitments
Employment
Agreements – Officers and Directors
As
of November 30, 2014, the Company had employment agreements with certain officers and directors (two individuals) containing the
following provisions:
|
Term
of contract
|
|
4
years, expiring on November 30, 2018
|
|
Salary
|
|
$275,000
commencing December 1, 2014
|
|
Salary
deferral
|
|
All
salaries will be accrued but may be paid from the Company’s available cash flow funds.
|
Annual
Salaries:
Name
|
|
Starting Dec. 1, 2014
|
|
|
2014-15
|
|
|
2015-2016
|
|
|
2016-2017
|
|
Robert Kohn
|
|
|
|
|
|
$
|
275,000
|
|
|
$
|
325,000
|
|
|
$
|
375,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Bonnie Nelson
|
|
|
|
|
|
$
|
275,000
|
|
|
$
|
325,000
|
|
|
$
|
375,000
|
|
The
accrued officers and directors payroll at February 29, 2016 is $2,156,082.
BioPower
Operations Corporation and Subsidiaries
Notes
to Consolidated Financial Statements
February
29, 2016
Unaudited
Lease
Agreement
On
June 3, 2013, the Company entered into a new lease agreement with its current landlord. The lease is for a 24 month period, expiring
on May 31, 2015 , and requires monthly base rental payments of $ 4,000 for the period from June 1, 2013 through May 31, 2014 and
$ 4,080 for the period from June 1, 2014 through May 31, 2015 plus adjustments for Common Area Expenses. On May 29, 2015, the
Company Amended the lease agreement extending it for an additional 12 month period, expiring May 31, 2016, and requiring monthly
base rental payments of $4,583 plus adjustments for Common Area Expenses.
Rent
expense was $14,336 and $12,821 for the three months ended February 29, 2016 and February 28, 2015, respectively.
Contingencies
From
time to time, the Company may be involved in legal matters arising in the ordinary course of business. While the Company believes
that such matters are currently not material, there can be no assurance that matters arising in the ordinary course of business
for which the Company is, or could be, involved in litigation, will not have a material adverse effect on its business, financial
condition or results of operations.
Note
9. Subsequent Events
On
March 2, 2016, Mr. Baruch Halpern joined the Company as Chief Operating Officer. For more than 20 years, Mr. Halpern has been
involved in equity research, advisory, capital raises, and has served as managing director of Halpern Capital, Inc., a boutique
investment banking firm founded by Mr. Halpern in 2002. He has also held senior finance positions at major corporations. Since
2009, Mr. Halpern has been managing director of CrossCredit Capital, LLC, a firm focused on structured financial solutions, and
since 2010 he has been managing director of Carbon Capital Advisors, LLC, a firm focused on green energy and carbon footprint
amelioration. He is a founder of Sustain:Green, a firm founded in 2012 offering financial products such as prepaid debit and credit
cards designed to fight climate change. Prior to founding Halpern Capital in 2002, Mr. Halpern held various sell-side analyst
positions. Additionally, he gained substantial buy-side experience as vice president and portfolio manager at Fred Alger &
Co., an investment advisory firm. At Fred Alger & Co., Mr. Halpern served as a research group leader, managing a $1 billion
portfolio with more than 600 companies in a broad range of industries. Mr. Halpern has an extensive corporate and industry background,
having also held positions with Celanese Corporation and Beech-Nut, Inc. He has served as a Director of RiceBran Technologies
(NASDAQ: RIBT) since 2012. Mr. Halpern received his masters of business administration in finance from Baruch College. Mr. Halpern
has been a CFA Charter holder since 1982 and holds numerous FINRA certifications.
As
part of Mr. Halpern’s Employment Contract, the Company authorized the issuance of 3,000,000 shares of its common stock to
remain in the possession of the Transfer Agent for one year. The 3,000,000 common shares will be released to Mr. Halpern after
one year as long as he does not voluntarily resign. At that time a standard two-year lock-up agreement will also be executed.
If Mr. Halpern voluntarily resigns before his first anniversary, there will be a claw-back of 2,250,000 common shares and Mr.
Halpern will be issued the remaining 750,000 common shares with a two-year lock-up agreement.
On
March 2, 2016, Mr. Halpern also loaned the Company $100,000 and entered into a convertible debt agreement at 8% interest, due
on March 2, 2018. The debt is convertible into common shares of stock at a conversion price of $0.15 per share. The loan includes
a provision for matching future conversion rights with any new loans made by the Company with the exception of a Right of First
Refusal. In addition, if an equity transaction is done at a price below $0.15 then the conversion price will adjust to such price.
On
March 11, 2016 we finalized an agreement awarding G3P a well installation and abandonment project in the amount of $17,800 to
install and abandon monitoring wells and write the reports for Broward County. G3P hired a sub-contractor to install the wells.
G3P completed the work on March 26, 2016.
On
April 8, 2016 we finalized two agreements
awarding G3P a waste remediation project for $458,525 to design and construct
a methane gas mitigation system including soil preparation. G3P has begun work on the project and will be responsible for the
design, procurement, and construction of the System. G3P is partnering with a construction company to complete the project. The
project is expected to be completed by our fiscal third quarter, 2016.